Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Rhea-AI Summary
Aptevo Therapeutics (NASDAQ:APVO) reported interim frontline AML data for mipletamig combined with venetoclax and azacitidine showing an 86% clinical benefit rate (CR/CRi/PR) among 28 evaluable patients and 0% cytokine release syndrome (CRS).
Key metrics: 79% CR/CRi, 61% CR, 55% of CR/CRi patients reached MRD-negative status, 35% of remissions had TP53 mutation, and four patients proceeded to allogeneic stem cell transplant. Data are interim and enrollment continues in the RAINIER program.
Positive
- 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline patients
- 0% of frontline patients experienced cytokine release syndrome (CRS)
- 79% achieved CR or CRi, with 61% achieving CR
- 55% of CR/CRi patients reached measurable residual disease-negative status
- Four patients proceeded to allogeneic stem cell transplant
Negative
- Interim dataset is small with only 28 evaluable frontline patients
- Results are early and from ongoing trials, so durability and broader safety remain unproven
News Market Reaction – APVO
On the day this news was published, APVO declined 22.79%, reflecting a significant negative market reaction. Argus tracked a peak move of +17.9% during that session. Argus tracked a trough of -43.6% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $7M at that time. Trading volume was exceptionally heavy at 35.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
APVO was up 5.23% while momentum‑screen peers KTTA and ADTX showed declines of 2.50% and 6.34%. Scanner data notes 2 peers moving down (median about -4.4%), suggesting APVO’s move was more stock‑specific than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Leadership transition | Positive | -10.3% | CEO succession and board changes alongside noted clinical and pipeline progress. |
| Jan 09 | Equity line financing | Positive | +5.0% | $60M equity line with Yorkville extending funding runway into 2029. |
| Dec 26 | Reverse stock split | Negative | -34.7% | 1‑for‑18 reverse split reducing share count from ~18M to ~1M. |
| Dec 09 | Clinical data update | Positive | -7.5% | RAINIER frontline AML data with high ORR, CR/CRi, MRD negativity and no CRS. |
| Nov 10 | Preclinical data debut | Positive | +6.1% | First trispecific APVO451 preclinical data showing tumor‑localized immune activation. |
News flow has been consistently constructive (clinical progress, financing, new platforms), but price reactions have been mixed, with several positive clinical/regulatory updates followed by negative or muted moves and structurally dilutive actions like a large reverse split.
Over the last six months, APVO has combined clinical progress in mipletamig with significant balance‑sheet and capital‑markets activity. A 1‑for‑18 reverse split on Dec 29, 2025 and a $60 million standby equity line reshaped the share structure and funding runway into 2029. Mipletamig data at ASH 2025 showed strong remission rates and no CRS yet drew a negative price reaction. Today’s AML update extends that efficacy/safety narrative against a backdrop of prior volatility around even positive news.
Market Pulse Summary
The stock dropped -22.8% in the session following this news. A negative reaction despite positive mipletamig data would fit a pattern where APVO’s constructive announcements have not always supported the share price, as seen after prior AML updates and leadership changes. Investors have previously focused on structural issues like the 1‑for‑18 reverse split and equity facility. In that context, strong 86% clinical benefit and 0 CRS in 28 patients might be overshadowed by longer‑term dilution and execution concerns.
Key Terms
cytokine release syndrome medical
acute myeloid leukemia medical
allogeneic stem cell transplant medical
measurable residual disease medical
tp53 medical
AI-generated analysis. Not financial advice.
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine
SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the combination has demonstrated robust clinical activity, delivering an
"The emerging mipletamig data in frontline AML are highly encouraging and highlight the differentiated profile we believe is needed to advance treatment in frontline AML," said Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics. "In this study we are observing strong remission rates in a growing number of evaluable patients together with a consistently favorable safety and tolerability profile, including the absence of cytokine release syndrome. Achieving meaningful clinical activity while maintaining this level of safety and tolerability is essential in the frontline AML setting, where therapies must be compatible with established regimens. These results reinforce our belief that mipletamig can be successfully combined with venetoclax and azacitidine, with the potential to enhance outcomes for older and/or unfit AML patients who continue to face poor prognosis and limited treatment options."
Huebner continued, "Importantly, four of the patients treated to date have proceeded to allogeneic stem cell transplant, which represents the best possible outcome in AML treatment and is rarely achieved in the older or unfit frontline patient population."
Data Highlights Include:
Among the evaluable frontline patient population treated to date (N=28), including 24 patients from the RAINIER trial and 4 patients from the completed dose expansion trial, mipletamig in combination with venetoclax and azacitidine has demonstrated:
100% of frontline patients have remained free of cytokine release syndrome (CRS)86% clinical benefit rate79% achieved CR or CRi61% achieved CR55% of patients who achieved CR/CRi had blast reductions that reached the important measurable residual disease-negative level, a result that is typically associated with stronger, more durable responses35% of patients with remissions had the TP53 genetic mutation, a high-risk biomarker typically associated with poor prognosis in AML and for which most treatment options frequently fail
Collectively, these data demonstrate mipletamig's potential to meaningfully enhance frontline AML treatment in older and/or unfit patients, by improving efficacy outcomes without materially increasing toxicity.
"Our frontline data show that mipletamig has the potential to play a meaningful role in the future frontline AML treatment," said Marvin White, President and Chief Executive Officer of Aptevo Therapeutics. "From the outset, our objective has been to develop an AML drug capable of integrating into the current standard-of-care and improving outcomes for patients who continue to face poor prognoses. The data reported reinforces our conviction that mipletamig may represent a differentiated approach with the potential to complement existing frontline therapies in a practical and impactful way. As enrollment continues, we remain focused on advancing our RAINIER trial and generating the data needed to support mipletamig's long-term role in AML treatment."
*(Clinical Benefit Rate: CR = complete remission; CRi = complete remission with incomplete blood marker recovery; PR = partial remission.)
Consistent Safety and Tolerability Profile Maintained Across Patients Treated to Date
In frontline patients treated to date, no cytokine release syndrome (CRS) has been observed. Together with strong efficacy outcomes, this outcome underscores mipletamig's safety and combinability, potentially offering a superior treatment in the future. This safety profile is particularly important in frontline AML, where tolerability and combinability are essential for treating older patients and/or those with comorbidities.
About the RAINIER Trial
RAINIER, a frontline AML study, is a Phase 1b/2 dose optimization, multi-center, multi-cohort, open label study. Subjects are adults aged 18 or older, newly diagnosed with AML who are not eligible for intensive induction chemotherapy. RAINIER will be conducted in two parts. First, a Phase 1b dose optimization study in frontline AML patients followed by a Phase 2 study. The Phase 1b trial consists of 28-day cycles of treatment across multiple, sequential cohorts.
About Mipletamig
Aptevo's wholly owned lead proprietary drug candidate, mipletamig, being evaluated for the treatment of AML, is differentiated by design™ to redirect the immune system of the patient to destroy leukemic cells and leukemic stem cells expressing the target antigen CD123, which is a compelling target for AML due to its overexpression on leukemic stem cells and AML blasts. This antibody-like recombinant protein therapeutic is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of CRS by use of the CRIS-7-derived CD3 binding pathway, an approach that differentiates Aptevo from competitors. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. Orphan drug designation provides key advantages-including the opportunity to seek U.S. market exclusivity for a specific period of time upon approval, FDA fee reductions, and access to development and tax credits. Mipletamig has been evaluated in more than 120 patients over three trials to date.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates and six preclinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIRand ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax and azacitidine on a targeted patient population will continue to show remissions, whether Aptevo's final trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of interim data readouts for ALG.APV-527, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises, geopolitical risks, including the current war between Russia and Ukraine, the United States and Iran, and any other military event that could evolve out of any of the current conflicts, and macroeconomic conditions such as economic uncertainty, imposition of tariffs, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
CONTACT:
Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
FAQ
What were the key efficacy results for APVO mipletamig in frontline AML reported on March 10, 2026?
How many frontline AML patients were evaluable in the APVO mipletamig analysis?
Did APVO report any cytokine release syndrome (CRS) with mipletamig plus venetoclax and azacitidine?
What proportion of APVO mipletamig remissions were MRD-negative and why is that important?
How many APVO patients proceeded to allogeneic stem cell transplant after mipletamig treatment?
